Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics (Nasdaq: FULC) announced a successful closing of a $68.5 million private placement with institutional and accredited investors. The offering involved the sale of 4,029,411 shares at $17.00 per share. Proceeds will support research and development, focusing on losmapimod for facioscapulohumeral muscular dystrophy and potential COVID-19 applications, as well as advancing other clinical programs. The company will register the resale of shares with the SEC within 15 days. Forward-looking statements highlight potential operational risks.
Fulcrum Therapeutics (Nasdaq: FULC) has submitted an Investigational New Drug (IND) application to initiate a Phase 3 trial for losmapimod as a treatment for COVID-19. This decision follows prior clinical trials showing its potential to reduce inflammatory cytokines linked to poor COVID-19 prognosis. The company is also advancing its development programs for facioscapulohumeral dystrophy (FSHD) and sickle cell disease, with key milestones on track for late 2020. Fulcrum expects its financial resources to support operations into Q1 2022.
Fulcrum Therapeutics (Nasdaq: FULC) announced significant data presentations at the 2020 American Academy of Neurology's virtual platform, showcasing progress in developing losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD). The data includes a pharmacodynamic biomarker for treatment effect and a standardized MRI protocol for muscle evaluation. The company is conducting Phase 2 trials assessing losmapimod's efficacy in FSHD, a rare genetic disease affecting 16,000-38,000 patients in the U.S.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its first quarter 2020 financial results on May 13, 2020, before the U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET, discussing these results and the latest corporate developments. The company is focused on treating genetically defined rare diseases, advancing its lead drug, losmapimod, to Phase 2 for facioscapulohumeral muscular dystrophy, while also working on FTX-6058 for sickle cell disease and beta-thalassemia.